Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Interleukin-27 Is a Potential Rescue Therapy for Acute Severe Colitis Through Interleukin-10-Dependent, T-Cell-Independent Attenuation of Colonic Mucosal Innate Immune Responses.

McLean MH, Andrews C, Hanson ML, Baseler WA, Anver MR, Senkevitch E, Staniszewska AK, Smith C, Davies LC, Hixon J, Li W, Shen W, Steidler L, Durum SK.

Inflamm Bowel Dis. 2017 Nov;23(11):1983-1995. doi: 10.1097/MIB.0000000000001274.

2.

Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10-Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells.

Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Cunha JP, Wasserfall C, Casares N, Lasarte JJ, Steidler L, Rottiers P, Dotta F, Gysemans C, Mathieu C.

Diabetes. 2017 Feb;66(2):448-459. doi: 10.2337/db15-1625. Epub 2016 Nov 8.

3.

Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis.

Robert S, Van Huynegem K, Gysemans C, Mathieu C, Rottiers P, Steidler L.

Benef Microbes. 2015;6(4):591-601. doi: 10.3920/BM2014.0083. Epub 2015 Feb 12.

PMID:
25576592
4.

Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case.

Robert S, Steidler L.

Microb Cell Fact. 2014 Aug 29;13 Suppl 1:S11. doi: 10.1186/1475-2859-13-S1-S11. Epub 2014 Aug 29. Review.

5.

Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice.

Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH, Atkinson MA, Dotta F, Rottiers P, Van Belle TL, Mathieu C.

Diabetes. 2014 Aug;63(8):2876-87. doi: 10.2337/db13-1236. Epub 2014 Mar 27.

6.

Engineering lactococci and lactobacilli for human health.

Bermúdez-Humarán LG, Aubry C, Motta JP, Deraison C, Steidler L, Vergnolle N, Chatel JM, Langella P.

Curr Opin Microbiol. 2013 Jun;16(3):278-83. doi: 10.1016/j.mib.2013.06.002. Epub 2013 Jul 11. Review.

PMID:
23850097
7.

Clinical development of lactocepin: a novel bacterial biologic?

Van Huynegem K, Steidler L.

Expert Rev Clin Immunol. 2012 Sep;8(7):597-9. doi: 10.1586/eci.12.55. No abstract available.

PMID:
23078055
8.

Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines.

von Schillde MA, Hörmannsperger G, Weiher M, Alpert CA, Hahne H, Bäuerl C, van Huynegem K, Steidler L, Hrncir T, Pérez-Martínez G, Kuster B, Haller D.

Cell Host Microbe. 2012 Apr 19;11(4):387-96. doi: 10.1016/j.chom.2012.02.006.

9.

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, Dotta F, Rottiers P, Gysemans C, Mathieu C.

J Clin Invest. 2012 May;122(5):1717-25. doi: 10.1172/JCI60530. Epub 2012 Apr 9.

10.

AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis.

Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, Watkins B, Sonis S, Coulie B, Rottiers P.

Oral Oncol. 2010 Jul;46(7):564-70. doi: 10.1016/j.oraloncology.2010.04.008. Epub 2010 Jun 9.

PMID:
20542722
11.

Actobiotics as a novel method for cytokine delivery.

Steidler L, Rottiers P, Coulie B.

Ann N Y Acad Sci. 2009 Dec;1182:135-45. doi: 10.1111/j.1749-6632.2009.05067.x.

PMID:
20074282
12.

Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis.

Rottiers P, De Smedt T, Steidler L.

Int Rev Immunol. 2009;28(6):465-86. doi: 10.3109/08830180903197498. Review.

PMID:
19954359
13.

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.

Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P.

Mucosal Immunol. 2010 Jan;3(1):49-56. doi: 10.1038/mi.2009.116. Epub 2009 Sep 30.

PMID:
19794409
14.

Immunomodulation by genetically engineered lactic acid bacteria.

Van Huynegem K, Loos M, Steidler L.

Front Biosci (Landmark Ed). 2009 Jun 1;14:4825-35. Review.

PMID:
19482589
15.

Characterization of ApuB, an extracellular type II amylopullulanase from Bifidobacterium breve UCC2003.

O'Connell Motherway M, Fitzgerald GF, Neirynck S, Ryan S, Steidler L, van Sinderen D.

Appl Environ Microbiol. 2008 Oct;74(20):6271-9. doi: 10.1128/AEM.01169-08. Epub 2008 Aug 8.

16.

Delivery of therapeutic proteins through Lactococcus lactis.

Neirynck S, Steidler L.

Biotechnol Genet Eng Rev. 2006;22:253-66. Review. No abstract available.

PMID:
18476334
17.

Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.

Waeytens A, Ferdinande L, Neirynck S, Rottiers P, De Vos M, Steidler L, Cuvelier CA.

Inflamm Bowel Dis. 2008 Apr;14(4):471-9.

PMID:
18092343
18.

Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization.

Frossard CP, Steidler L, Eigenmann PA.

J Allergy Clin Immunol. 2007 Apr;119(4):952-9. Epub 2007 Feb 20.

PMID:
17316776
19.

Therapeutic drug delivery by genetically modified Lactococcus lactis.

Steidler L, Rottiers P.

Ann N Y Acad Sci. 2006 Aug;1072:176-86. Review.

PMID:
17057198
20.

Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.

Termont S, Vandenbroucke K, Iserentant D, Neirynck S, Steidler L, Remaut E, Rottiers P.

Appl Environ Microbiol. 2006 Dec;72(12):7694-700. Epub 2006 Oct 6.

21.

Comparative and functional analysis of sortase-dependent proteins in the predicted secretome of Lactobacillus salivarius UCC118.

van Pijkeren JP, Canchaya C, Ryan KA, Li Y, Claesson MJ, Sheil B, Steidler L, O'Mahony L, Fitzgerald GF, van Sinderen D, O'Toole PW.

Appl Environ Microbiol. 2006 Jun;72(6):4143-53.

22.

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L.

Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9. Epub 2006 May 22.

PMID:
16716759
23.
24.

Altered gut transcriptome in spondyloarthropathy.

Laukens D, Peeters H, Cruyssen BV, Boonefaes T, Elewaut D, De Keyser F, Mielants H, Cuvelier C, Veys EM, Knecht K, Van Hummelen P, Remaut E, Steidler L, De Vos M, Rottiers P.

Ann Rheum Dis. 2006 Oct;65(10):1293-300. Epub 2006 Feb 13.

25.

Delivery of therapeutic proteins to the mucosa using genetically modified microflora.

Steidler L.

Expert Opin Drug Deliv. 2005 Jul;2(4):737-46. Review.

PMID:
16296798
26.

In situ delivery of therapeutic cytokines by genetically engineered Lactococcus lactis.

Steidler L.

Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(3b):551, 553-6. No abstract available.

PMID:
15954652
27.

Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10.

Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP.

Eur J Pharm Biopharm. 2005 Aug;60(3):349-59.

PMID:
15927456
28.

Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis.

Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP.

Eur J Pharm Biopharm. 2005 Jan;59(1):9-15.

PMID:
15567296
29.

CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease.

Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D, Demetter P, Cuvelier C, Van Den Berghe M, Rottiers P, Veys EM, Remaut E, Steidler L, De Keyser F, De Vos M.

Ann Rheum Dis. 2005 Jun;64(6):930-5. Epub 2004 Nov 11.

30.

Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.

Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L.

Gastroenterology. 2004 Aug;127(2):502-13.

PMID:
15300583
31.
32.
33.

Genetically engineered probiotics.

Steidler L.

Best Pract Res Clin Gastroenterol. 2003 Oct;17(5):861-76. Review.

PMID:
14507594
34.

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.

Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E.

Nat Biotechnol. 2003 Jul;21(7):785-9. Epub 2003 Jun 15.

PMID:
12808464
35.
36.

Cytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel disease.

O'Neil D, Steidler L.

Adv Exp Med Biol. 2003;520:252-85. Review. No abstract available.

PMID:
12613583
37.

In situ delivery of cytokines by genetically engineered Lactococcus lactis.

Steidler L.

Antonie Van Leeuwenhoek. 2002 Aug;82(1-4):323-31. Review.

PMID:
12369199
38.

Overexpression of alpha(1)-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis.

Hochepied T, Wullaert A, Berger FG, Baumann H, Brouckaert P, Steidler L, Libert C.

Gut. 2002 Sep;51(3):398-404.

39.

Microbiological and immunological strategies for treatment of inflammatory bowel disease.

Steidler L.

Microbes Infect. 2001 Nov;3(13):1157-66. Review.

PMID:
11709296
40.

Secretion of biologically active murine interleukin-10 by Lactococcus lactis.

Schotte L, Steidler L, Vandekerckhove J, Remaut E.

Enzyme Microb Technol. 2000 Dec;27(10):761-765.

PMID:
11118583
41.

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E.

Science. 2000 Aug 25;289(5483):1352-5.

42.

Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine.

Steidler L, Robinson K, Chamberlain L, Schofield KM, Remaut E, Le Page RW, Wells JM.

Infect Immun. 1998 Jul;66(7):3183-9.

43.
46.

Production of soluble and active recombinant murine interleukin-2 in Escherichia coli: high level expression, Kil-induced release, and purification.

Robbens J, Raeymaekers A, Steidler L, Fiers W, Remaut E.

Protein Expr Purif. 1995 Aug;6(4):481-6.

PMID:
8527934
47.

Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis.

Steidler L, Wells JM, Raeymaekers A, Vandekerckhove J, Fiers W, Remaut E.

Appl Environ Microbiol. 1995 Apr;61(4):1627-9.

48.

Supplemental Content

Loading ...
Support Center